To address this, we used tazemetostat for 3 weeks to inhibit EZH2 in two neuroblastoma cell lines with long telomeres containing doxycycline-inducible MYCN transgene (SKNMMMYCN and SKNJCIMYCN). The gene discussed is EZH2; the disease is neuroblastoma.